Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 28INDUSTRY 28NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Thyroid Neoplasms 1Endometrial Adenocarcinoma 1Carcinoma, Medullary 1

Interventions

Radiotherapy 214Cisplatin 180Cyclophosphamide 169Doxorubicin 138Vincristine 127Paclitaxel 125Filgrastim 121Etoposide 104Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NETWORK × nintedanib × Clear all
NCT01788982 2020-07-31

Nintedanib(BIBF1120) in Thyroid Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
100 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

NCT01225887 2017-10-09

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
37 enrolled 11 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡